What the Research Says
L-Ornithine is an amino acid integral to the urea cycle and has been extensively studied for its therapeutic applications. A systematic review by Butterworth et al. (2020) involving six randomized controlled trials (RCTs) with 384 participants demonstrated that L-ornithine L-aspartate (LOLA) significantly reduced the risk of overt hepatic encephalopathy progression compared to placebo or no intervention. Similarly, He et al. (2024) conducted a meta-analysis of six RCTs involving 292 patients and reported that LOLA improved minimal hepatic encephalopathy reversal with a relative risk of 2.264 and reduced overt progression with a relative risk of 0.220.
In the context of exercise performance, Sugino et al. (2008) demonstrated that L-ornithine supplementation attenuated physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism. Additionally, Miyake et al. (2014) found that a low dose of 400 mg of L-ornithine improved sleep quality in healthy workers.
Despite these findings, larger-scale RCTs are needed to confirm the exercise performance benefits and further establish the efficacy of L-ornithine across diverse applications.
